Hepatitis B virus (HBV) has evolved a unique life cycle that results in the production of
enormous viral loads during active replication without actually killing the infected cell …

HBV has evolved a unique life cycle that results in the production of enormous viral loads
during active replication without actually killing the infected cells directly. Two of the key …

Background Entecavir is a potent and selective guanosine analogue with significant activity
against hepatitis B virus (HBV). Methods In this phase 3, double-blind trial, we randomly …

Background & Aims: Entecavir is a nucleoside analogue with potent in vitro activity against
lamivudine-resistant hepatitis B virus (HBV). This randomized, dose-ranging, phase 2 study …

Background Whereas 40 million individuals are estimated to be infected with HIV worldwide,
nearly 400 million people are chronic HBV carriers [10]. HBV and HIV are endemic in the …

Antiviral drug resistance now poses a major problem for the management of patients with
chronic hepatitis B. In theory, resistance may be prevented if a sufficiently potent antiviral …

AIM: To observe the efficiency and safety of thymosin-α1 treatment in patients with hepatitis
B e antigen (HBeAg) and HBV DNA positive chronic hepatitis. METHODS: Sixty-two patients …

The global health challenge posed by the hepatitis B virus (HBV) centres around the
widespread distribution and the serious complications as a result of persistent infection with …

The clinical management of chronic hepatitis B infection has entered a new era with the
introduction and widespread use of oral nucleoside analogues such as lamivudine and …

AIM: To observe the inhibition of hepatitis B virus (HBV) replication and expression by
combination of siRNA and lamivudine in HepG2. 2.15 cells. METHODS: Recombinant …